Vir Biotechnology
San Francisco
About Vir Biotechnology
Vir Biotechnology leverages the immense potential of the immune system to address critical unmet medical needs and improve patient outcomes Our pipeline is built on two technology platforms which enable us to rapidly identify, optimize and advance candidates from concepts to the clinic: our next-generation antibody platform and the PRO-XTEN™ protease-releasable masking technology in infectious diseases and cancer, respectively. We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in infectious diseases, with a leading program in chronic hepatitis delta, are complemented by strategic programs in oncology. We have broken ground in immunology, demonstrating our ability to discover, engineer and develop antibody-based medicines for two of the greatest health challenges of our time: COVID-19 and Ebola. Every day, we work with the utmost urgency to deliver potentially transformative medicines for patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $1.2B
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2026)
- Ticker: nasdaq:VIR
- Website: vir.bio
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/vir-biotechnology-87887 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.